Genitourinary Syndrome of Menopause

Learning objectives

By the end of this module you will be able to

L01Ask about genitourinary symptoms proactively using a normalising question.
L02Explain that GSM, unlike VMS, is progressive and does not resolve without treatment.
L03Prescribe local oestrogen with a correct loading and maintenance schedule.
L04State the evidence that vaginal oestrogen reduces recurrent UTI in postmenopausal women.
L05Frame the vaginal oestrogen decision in breast cancer survivors, including who to involve.

Scope

Topics covered

01Terminology shift from vulvovaginal atrophy to GSM and why it matters

02Vaginal and urothelial oestrogen receptor biology

03Local oestrogen: creams, pessaries, rings — systemic absorption data

04Prasterone (DHEA) and ospemifene

05Moisturisers vs lubricants — different products, different uses

06Recurrent UTI prevention in postmenopausal women

07Vaginal oestrogen after breast cancer: the nuanced conversation

08Vaginal laser: what the regulators said

Module narrative

How this plays out in practice

Primary care view· your track

Ask every postmenopausal woman a direct, normalising question: 'Many women get vaginal dryness, discomfort with sex, or urinary symptoms after menopause — is any of that affecting you?' First-line treatment is local estradiol (10 microgram pessary nightly for two weeks, then twice weekly) or estriol cream, continued indefinitely. Add a vaginal moisturiser for tissue hydration and a lubricant for intercourse — they are not interchangeable.

Specialist view

For refractory GSM, options include prasterone 6.5 mg intravaginal daily, ospemifene 60 mg orally (avoid with existing VTE risk, and note the vasomotor side effect), and pelvic floor physiotherapy for the muscular component. In survivors of ER-positive breast cancer, most guidelines permit local oestrogen after non-hormonal measures fail, with oncology involvement — this is more nuanced on aromatase inhibitors than on tamoxifen, since AIs depend on profound oestrogen suppression.

Advanced note

Systemic absorption from low-dose vaginal estradiol is highest during the initial loading phase, when the epithelium is thin, and falls as maturation occurs — the opposite of clinical intuition. Observational cohort data (WHI Observational Study, Nurses' Health Study analyses) show no increase in cardiovascular events, VTE or breast cancer with vaginal oestrogen, and several regulators have narrowed their class labelling accordingly.

Expected takeaways

What you should walk away believing

→Up to 80% of postmenopausal women have GSM; fewer than a quarter raise it unprompted, so you must ask.
→Local oestrogen produces serum levels within the postmenopausal range and does not require a progestogen for endometrial protection.
→Vaginal oestrogen reduces recurrent UTI recurrence substantially — a hard clinical endpoint, not a comfort measure.
→Treatment is indefinite: symptoms return within weeks to months of stopping because the underlying atrophy returns.
→Energy-based vaginal devices have not demonstrated benefit over sham in the better trials, and regulators have issued safety warnings.

Myth-buster

What patients — and colleagues — get wrong

The claim

“Vaginal dryness gets better on its own like hot flushes do.”

Reality

GSM is progressive. VMS typically remits over years; urogenital atrophy worsens with continued oestrogen deprivation and reverses only with treatment. This distinction is essential when setting expectations about indefinite therapy.

Graded claims

Evidence grading for this module

A

Low-dose vaginal oestrogen relieves GSM symptoms

Established — RCT / guideline-grade — Multiple RCTs and Cochrane review.

A

Vaginal oestrogen reduces recurrent UTI in postmenopausal women

Established — RCT / guideline-grade — RCT evidence (Raz & Stamm) plus guideline endorsement.

F

Vaginal oestrogen requires added progestogen for endometrial protection

Refuted or actively misleading — Not required at licensed low doses in women with an intact uterus.

B

Prasterone improves dyspareunia

Supported in defined populations — Licensed on RCT evidence for moderate-severe dyspareunia.

E

Fractional CO2 laser is superior to sham for GSM

Popular, weak or conflicting support — Best-quality sham-controlled trials show no difference; FDA safety communication issued.

E

Vaginal oestrogen is absolutely contraindicated after breast cancer

Popular, weak or conflicting support — Most guidelines permit it after non-hormonal failure, with oncology input.

Evidence summary

Graded claims, key takeaways and sources for this module.

Open printable summary

Clinical vignettes

Apply it in clinic

GSM on an aromatase inhibitor

A 61-year-old, 4 years after ER-positive breast cancer on letrozole, has severe dyspareunia that has ended sexual intimacy, and moisturisers have failed.

Most appropriate approach?

Self-assessment

Check your recall

Q1

A 62-year-old with dyspareunia and three UTIs this year. Which intervention has RCT support for both problems?

Q2

Correct advice about duration of vaginal oestrogen therapy?

Q3

A woman with an intact uterus using 10 microgram vaginal estradiol pessaries twice weekly needs:

Flashcards

Retrieval practice

Card 1 / 5

Reviewed 0 / 5

Glossary

Terms used in this module

GSM: Genitourinary syndrome of menopause — vulvovaginal, sexual and urinary symptoms attributable to oestrogen deficiency.
Prasterone: Intravaginal DHEA converted locally to sex steroids by the vaginal epithelium.
Ospemifene: Oral selective oestrogen receptor modulator licensed for moderate-severe dyspareunia due to GSM.

Primary sources